New hope for tough blood cancers: experimental drug targets patients who failed first therapy
NCT ID NCT03770429
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 22 times
Summary
This study tests an experimental drug called AZD6738 in adults with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard frontline therapy. The main goal is to check the drug's safety and find the right dose. About 52 participants will take the drug and be monitored for side effects and how their cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BIDMC
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.